NRx Pharmaceuticals To Present Keynote Address On Ketamine Efficacy And Risks At Upcoming Sachs Neuroscience Innovation Forum In San Francisco
Portfolio Pulse from Benzinga Newsdesk
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) will present a keynote address on ketamine's efficacy and risks for treating suicidal depression at the Sachs Neuroscience Innovation Forum. The company plans to file a New Drug Application for ketamine in 2024 in the US and EU. NRx has shown ketamine's superiority to placebo and non-inferiority to electroshock therapy in trials. They are developing a new formulation with Nephron Pharmaceuticals and a REMS program. NRx has created HOPE Therapeutics, Inc. to advance ketamine's development and will award rights to shareholders and new investors. NRx is also developing NRX-101 for suicidal bipolar depression and chronic pain, in partnership with Alvogen Pharmaceuticals.
January 02, 2024 | 1:45 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
NRx Pharmaceuticals is set to present on ketamine's benefits and risks at an upcoming forum, with plans to file a New Drug Application in 2024. The company is developing a new ketamine formulation and a REMS program, and has created HOPE Therapeutics to further drug development.
The announcement of the keynote address and the progress in ketamine's development, including the planned New Drug Application, are likely to be viewed positively by investors. The partnership with Nephron Pharmaceuticals and the creation of HOPE Therapeutics could also be seen as strategic moves to strengthen the company's position in the market. The news is highly relevant and important to NRx Pharmaceuticals, and there is a high level of confidence that this will have a positive short-term impact on the stock price.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100